PMID- 20740585
OWN - NLM
STAT- MEDLINE
DCOM- 20100915
LR  - 20100826
IS  - 1096-9098 (Electronic)
IS  - 0022-4790 (Linking)
VI  - 102
IP  - 3
DP  - 2010 Sep 1
TI  - Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular 
      carcinoma.
PG  - 264-70
LID - 10.1002/jso.21623 [doi]
AB  - BACKGROUND AND OBJECTIVES: The purpose of this study was to investigate genetic 
      impact of monocyte chemoattractant protein-1 (MCP-1) and its receptor chemokine 
      receptor-2 (CCR2) gene polymorphisms on the susceptibility and 
      clinicopathological characteristics of hepatocellular carcinoma (HCC). METHODS: A 
      total of 446 subjects, including 344 healthy controls and 102 patients with HCC, 
      were recruited in this study and subjected to PCR-RFLP to estimate the impact of 
      these two polymorphic variants on HCC. RESULTS: No relationship between MCP-1 
      -2518G/A gene polymorphism and HCC risk was found among our recruited HCC 
      patients and healthy controls. However, there was a significantly increased risk 
      (AOR = 1.91; 95% CI = 1.11-3.29) of having HCC among subjects with GA 
      heterozygotes of CCR2 V64I after adjusting for other confoundings. There was no 
      synergistic effect between gene polymorphism and environmental risk factors, 
      including tobacco and alcohol consumptions, as well as clinicopathological 
      parameters of HCC for MCP-1 -2518G/A and CCR2 V64I genes, respectively. 
      CONCLUSIONS: CCR2-64I gene polymorphism is an important factor for the 
      susceptibility of HCC but it might not influence the clinical pathological 
      progression of HCC, and the contribution of CCR2-64I gene polymorphism on the 
      susceptibility of HCC could be not through the affection of liver injury-related 
      clinical pathological characteristics.
CI  - 2010 Wiley-Liss, Inc.
FAU - Yeh, Chao-Bin
AU  - Yeh CB
AD  - Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, ROC.
FAU - Tsai, Hsiu-Ting
AU  - Tsai HT
FAU - Chen, Yi-Chen
AU  - Chen YC
FAU - Kuo, Wu-Hsien
AU  - Kuo WH
FAU - Chen, Tzy-Yen
AU  - Chen TY
FAU - Hsieh, Yi-Hsien
AU  - Hsieh YH
FAU - Chou, Ming-Chih
AU  - Chou MC
FAU - Yang, Shun-Fa
AU  - Yang SF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Surg Oncol
JT  - Journal of surgical oncology
JID - 0222643
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCR2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Receptors, CCR2)
SB  - IM
MH  - Carcinoma, Hepatocellular/*genetics/pathology
MH  - Chemokine CCL2/genetics
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Liver Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Receptors, CCR2/*genetics
EDAT- 2010/08/27 06:00
MHDA- 2010/09/17 06:00
CRDT- 2010/08/27 06:00
PHST- 2010/08/27 06:00 [entrez]
PHST- 2010/08/27 06:00 [pubmed]
PHST- 2010/09/17 06:00 [medline]
AID - 10.1002/jso.21623 [doi]
PST - ppublish
SO  - J Surg Oncol. 2010 Sep 1;102(3):264-70. doi: 10.1002/jso.21623.